Trending / Immunology / Discovery Changes What We Knew About B Cell Activation. MAR 14, 2023 10:00 AM PDT. Share . Discovery Changes What We Knew About B Cell Activation. WRITTEN BY: Carmen Leitch 3.

Researchers uncover immune cell marker and regulator of anti-tumor immunity Date: June 23, 2023 Source: Mass General Brigham Summary: B cells are thought to play a critical role in innate and ...

Acute fulminant myocarditis (AFM) is characterized by sudden, severe cardiac inflammation causing hemodynamic instability or arrhythmia. 1 Currently, no approved medical therapy exists for AFM. Janus ...

DESTIN, Fla. — An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according to a speaker at the Congress of Clinical Rheumatology ...

A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukemia (B-ALL), the commonest cancer in childhood and one that can be ...

The review concludes that CD20-targeted chimeric antigen receptor (CAR) T-cell therapy is an option worth exploring, despite potential safety concerns that warrant more extensive research.

Obecabtagene autoleucel, a novel CD19-directed CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: the future for reducing toxicity and T-cell exhaustion?, Expert ...

Intravascular large B-cell lymphoma (IVLBCL) is a rare type of non-Hodgkin's lymphoma. Learn about symptoms, diagnosis, treatment, and outlook.

The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy, especially the risk of T-cell neoplasms related to viral vector integration, is an emerging concern.We reviewed our c ...

Feb. 13, 2025 -- The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL). The treatment combines a medicine ...